Loading stock data…
Celldex Therapeutics, Inc. (CLDX)
$39.12-0.56 (-1.41%)
Market ClosedLast close Sep 8
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Celldex Therapeutics, Inc. in the Healthcare sector is trading at $39.12 with a market capitalization of $2.3B. Wall Street consensus targets $58.79 (14 analysts), implying a +50.3% move over the next 12 months. The stock is currently 13% below its 52-week high of $45.14, remaining 23.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +50.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22,000↑ | $15,000↓ | $121,000 | $0↓ | $730,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$80.62M↑ | -$84.44M↑ | -$87.15M↓ | -$73.62M↓ | -$63.86M |
| Net Income | -$73.50M↑ | -$78.69M↑ | -$81.32M↓ | -$67.04M↓ | -$56.60M |
Peer Comparison
JNJUNHPFE
Fundamentals
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific ant...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.98
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-62.17%
Volume
Today's trading volume
833,635
Recent News
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results
Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock’s recent strength in sharper focus for investors. See our latest analysis for Celldex Therapeutics. Celldex Therapeutics shares have climbed strongly over the past year, with a year to date share price return of 54.42% and a 1 year total shareholder return of 101.89%. The recent 90 day share price gain of 29.21% suggests momentum has been...
Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?
Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operations increased to US$0.94. Over the first half of 2026, revenue slipped to just US$0.037 million as the company’s net loss rose to US$152.19 million, highlighting the cost intensity of its operations relative to minimal reported revenue. We will examine how this widening net loss and sharply...
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return
Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises questions about how much of its pipeline story is already reflected in the current price. The share price has returned 101.9% over the past year, which sets a high bar for any further upside to be justified by future execution. Progress in Celldex Therapeutics' allergy and immunology programs, including ongoing late stage studies and early...
What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?
Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 studies for barzolvolimab following its latest development review. Celldex discontinued its Phase 2 trial in prurigo nodularis after the program did not show sufficient efficacy. For readers who want to see more stock ideas linked to similar healthcare themes, the next step is to explore 43...
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?